Source:http://linkedlifedata.com/resource/pubmed/id/11450095
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2001-7-13
|
pubmed:abstractText |
Our experiments were performed to test the hypothesis that human beta-amyloid peptide 42 (beta A) is able to enter and exit the brain parenchyma through the blood-brain barrier. In an effort to determine the effect of beta A in an animal model, we have injected beta A i.v. into rats following single and repeated brain ischemia. Rats were sacrificed at 3 and 12 months after injection and beta A was localized by monoclonal antibody (mAb) 4G8. The present observations revealed an abundant presence of beta A in the extracellular space of the brain, which appeared to be dilated, and a vigorous uptake of beta A into the cytoplasm of endothelial and ependymal cells, pericytes, astrocytes and neurons. Some of the beta A deposits were associated and/or had migrated to the vessels and to the ventricles, and by 3 months a significant amount of beta A was directly associated with the vessels and was observed inside the ventricular space. Virtually no soluble and aggregating beta A was found in brain tissue 1 year later. This suggests that phagocytic pericytes and astrocytes take up exogenous beta A in an attempt to clear the peptide from the brain extracellular space and deliver it to the circulation. Further, direct removal of beta A from the ventricles by the bloodstream is also possible. These observations suggest that a reverse transport of beta A across endothelial cells of microvessels represents one of the possible mechanisms responsible for removal of extravasated beta A. The findings of the present study indicate that in normal conditions beta A is rapidly cleared from the cerebrospinal fluid and brain parenchyma, suggesting that irreversible changes in the physico-chemical properties of the cerebrovascular endothelial cell surface are involved in beta A deposition in the brain in Alzheimer's disease (AD).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0065-1419
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
76
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
73-7
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:11450095-Alzheimer Disease,
pubmed-meshheading:11450095-Amyloid beta-Peptides,
pubmed-meshheading:11450095-Animals,
pubmed-meshheading:11450095-Blood-Brain Barrier,
pubmed-meshheading:11450095-Brain,
pubmed-meshheading:11450095-Cerebral Ventricles,
pubmed-meshheading:11450095-Endothelium, Vascular,
pubmed-meshheading:11450095-Female,
pubmed-meshheading:11450095-Ischemic Attack, Transient,
pubmed-meshheading:11450095-Peptide Fragments,
pubmed-meshheading:11450095-Rats,
pubmed-meshheading:11450095-Rats, Wistar
|
pubmed:year |
2000
|
pubmed:articleTitle |
Possible reverse transport of beta-amyloid peptide across the blood-brain barrier.
|
pubmed:affiliation |
Department of Neuropathology, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|